

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. Peace Health Ketchikan Medical Center</p> <p>2. 3100 Tongass Avenue Ketchikan, Alaska 99901-5794</p>	<p>In accordance with letter dated June 13, 2011</p> <p>3. License number 50-19913-01 is amended in its entirety to read as follows:</p> <p>4. Expiration date August 31, 2012</p> <p>5. Docket No. 030-19521 Reference No.</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p>
<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p>	
<p>9. Authorized use:</p> <p>A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.</p> <p>B. Any imaging and localization study permitted by 10 CFR 35.200.</p>	

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 3100 Tongass Avenue, Ketchikan, Alaska.
11. The Radiation Safety Officer for this license is Lars Gustaf Crabo, M.D.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user, authorized nuclear pharmacist, and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number
50-19913-01

Docket or Reference Number
030-19521

Amendment No. 47

B. The following individuals are authorized users for the material and medical uses indicated:

<u>Authorized Users</u>	<u>Material and Use</u>
Gregory Deke Kienzle, M.D.	35.100; 35.200
Jon E. Ekstrom, M.D.	35.100; 35.200
Rodger W. Shaver, M.D.	35.100; 35.200
Loulie B. Molloy, M.D.	35.100; 35.200
Charles McGlade, M.D.	35.100; 35.200
Ronald Lewis, M.D.	35.100; 35.200
Gary Baker, M.D.	35.100; 35.200
Bernardo Isuani, M.D.	35.100; 35.200
Mathews B. Fish, M.D.	35.100; 35.200
Cathryn L. Chicola, M.D.	35.100; 35.200
Richard D. Clark, M.D.	35.100; 35.200
Charles E. Deaton, M.D.	35.100; 35.200
Robert Gunderman, M.D.	35.100; 35.200
Phillip J. Keizer, Jr., M.D.	35.100; 35.200
James D. Kippen, M.D.	35.100; 35.200
Gregory M. Kisling, D.O.	35.100; 35.200
Barbara Michaelis, M.D.	35.100; 35.200
Lee G. Michels, M.D.	35.100; 35.200
L. Paul Wilson, M.D.	35.100; 35.200
Gill Morgan Taylor-Tyree Sr., M.D.	35.100; 35.200
William Gray Mason, M.D.	35.100; 35.200
John D. Gorman, M.D.	35.100; 35.200
David W. Tsai, M.D.	35.100; 35.200
Stephen G. Thiede, M.D.	35.100; 35.200
John G. Grimme, M.D.	35.100; 35.200
Akshay S. Gupta, M.D.	35.100; 35.200
Martin Kernberg, M.D.	35.100; 35.200
Stephanie Telesetsky Young, M.D.	35.100; 35.200
Matthew John Thomson, M.D.	35.100; 35.200
Lars Gustaf Crabo, M.D.	35.100; 35.200
Peter Christopher Beutow, M.D.	35.100; 35.200
Gregory Deke Kienzle, M.D.	35.100; 35.200
Jonathon T Franklin, M.D.	35.100; 35.200
Richard Kelly, M.D.	35.100; 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
50-19913-01Docket or Reference Number
030-19521

Amendment No. 47

Authorized UsersMaterial and Use

David George Ashley, M.D.	35.100; 35.200
Jason Marsh Stoane, M.D.	35.100; 35.200
Dag Andre Jensen, M.D.	35.100; 35.200
Kenneth D. Carpenter, M.D.	35.100; 35.200
Valerie Smith Behrndt, M.D.	35.100; 35.200
David Daskam Calahan, M.D.	35.100; 35.200
Laura Kay Backer, M.D.	35.100; 35.200
Kathryn Ann Bossolt Cambron, M.D.	35.100; 35.200
Robert Milton Hughes, M.D.	35.100; 35.200
Mathew Thomas Studley, M.D.	35.100; 35.200
Charles Ariz, M.D.	35.100; 35.200
Gita R. Rabbani, M.D.	35.100; 35.200
Michael Ted Smith, M.D.	35.100; 35.200
Kai-Ling Ng, M.D.	35.100; 35.200
Patricia Rausch Geraghty, M.D.	35.100; 35.200
Kevin L. Ketchum, M.D.	35.100; 35.200

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing financial assurance for decommissioning.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
50-19913-01Docket or Reference Number
030-19521

Amendment No. 47

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated March 18, 2002
- B. Letter received January 29, 2003
- C. Letter received April 2, 2003
- D. Letters dated November 4, 2003
- E. Letter dated December 2, 2004
- F. Letter dated August 4, 2005
- G. Letters dated September 11, 2006
- H. Letter dated November 1, 2006
- I. Facsimile dated August 15, 2008
- J. Letter dated October 2, 2009

(ML062580113)
(ML063470448)
(ML082490277)
(ML093130136)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

/RA/

Date August 12, 2011

By

Lizette Roldán-Otero, Ph.D. Health Physicist
Nuclear Materials Safety Branch B
Region IV
Arlington, Texas 76011-4125